|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's range||224.56 - 228.61|
|52-week range||198.64 - 258.45|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||19.30|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||7.76 (3.42%)|
|Ex-dividend date||17 Aug 2022|
|1y target est||253.12|
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Amgen (AMGN) closed at $224.46 in the latest trading session, marking a -1.43% move from the prior day.
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.